Education
About Us
Working with TipRanks
Follow Us
Cypherpunk Technologies Inc. (CYPH)
:CYPH
CYPH Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
CYPH FAQ
What was Cypherpunk Technologies Inc.’s price range in the past 12 months?
Currently, no data Available
What is Cypherpunk Technologies Inc.’s market cap?
Currently, no data Available
When is Cypherpunk Technologies Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cypherpunk Technologies Inc.’s earnings last quarter?
Currently, no data Available
Is Cypherpunk Technologies Inc. overvalued?
According to Wall Street analysts Cypherpunk Technologies Inc.’s price is currently Undervalued.
Does Cypherpunk Technologies Inc. pay dividends?
Cypherpunk Technologies Inc. does not currently pay dividends.
What is Cypherpunk Technologies Inc.’s EPS estimate?
Cypherpunk Technologies Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cypherpunk Technologies Inc. have?
Currently, no data Available
What happened to Cypherpunk Technologies Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cypherpunk Technologies Inc.?
Currently, no hedge funds are holding shares in CYPH
Company Description
Cypherpunk Technologies Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.